CRSP241018C40000
- 8.85
- +1.31+17.37%
CRISPR Therapeutics Newsroom
CRISPR Therapeutics Analyst Ratings
RBC Cuts Price Target on CRISPR Therapeutics to $53 From $60, Keeps Sector Perform Rating
CRISPR Therapeutics Analyst Ratings
Truist Adjusts Price Target on CRISPR Therapeutics to $100 From $120, Maintains Buy Rating
Crispr Therapeutics AG: Strategic Progress and Strong Financials Bolstering a Buy Rating
Crispr Therapeutics AG Poised for Growth: Foroohar Maintains Buy Rating Amid Pipeline Progress and Strong Financials
A Quick Look at Today's Ratings for CRISPR Therapeutics(CRSP.US), With a Forecast Between $30 to $105
Crispr Therapeutics AG (CRSP) Receives a Buy From Piper Sandler
Crispr Therapeutics Price Target Cut to $94.00/Share From $112.00 by Chardan Capital
CRISPR Therapeutics Analyst Ratings
Barclays Sticks to Its Hold Rating for Crispr Therapeutics AG (CRSP)
Chardan Research Adjusts Price Target on CRISPR Therapeutics to $94 From $112, Maintains Buy Rating
Buy Rating Affirmed for Crispr Therapeutics AG Amid Strong Commercial Prospects and Robust Pipeline Growth
Rodman & Renshaw Initiates CRISPR Therapeutics at Buy With $90 Price Target
TD Cowen Maintains CRISPR Therapeutics(CRSP.US) With Sell Rating, Maintains Target Price $30
CRISPR Therapeutics Analyst Ratings
CRISPR Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Medtronic (MDT), Crispr Therapeutics AG (CRSP) and Tango Therapeutics (TNGX)
CRISPR Therapeutics Analyst Ratings
Citigroup Maintains Buy on CRISPR Therapeutics, Lowers Price Target to $84